BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26218951)

  • 1. Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010.
    Murphy Y; Goldner EM; Fischer B
    Pain Physician; 2015; 18(4):E605-14. PubMed ID: 26218951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review.
    Fischer B; Argento E
    Pain Physician; 2012 Jul; 15(3 Suppl):ES191-203. PubMed ID: 22786457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later.
    Fischer B; Gooch J; Goldman B; Kurdyak P; Rehm J
    Can J Public Health; 2014 Apr; 105(2):e146-9. PubMed ID: 24886852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016.
    Fischer B; Jones W; Vojtila L; Kurdyak P
    Pain Physician; 2018 May; 21(3):219-228. PubMed ID: 29871366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working?
    Fischer B; Ialomiteanu A; Kurdyak P; Mann RE; Rehm J
    Subst Abuse Treat Prev Policy; 2013 Feb; 8():7. PubMed ID: 23406368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription opioid dispensing in Canada: an update on recent developments to 2018.
    Jones W; Vojtila L; Kurdyak P; Fischer B
    J Pharm Policy Pract; 2020; 13():68. PubMed ID: 33110608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011.
    Fischer B; Jones W; Urbanoski K; Skinner R; Rehm J
    Drug Alcohol Rev; 2014 Jan; 33(1):19-26. PubMed ID: 24261474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada.
    Fischer B; Jones W; Tyndall M; Kurdyak P
    BMC Public Health; 2020 Jan; 20(1):143. PubMed ID: 32005211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription opioid prescribing, use/misuse, harms and treatment among Aboriginal people in Canada: a narrative review of available data and indicators.
    Russell C; Firestone M; Kelly L; Mushquash C; Fischer B
    Rural Remote Health; 2016; 16(4):3974. PubMed ID: 27871180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?
    Fischer B; Keates A; Bühringer G; Reimer J; Rehm J
    Addiction; 2014 Feb; 109(2):177-81. PubMed ID: 23692335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the prevalence of nonmedical prescription opioid use in the general Canadian population: methodological issues and questions.
    Fischer B; Nakamura N; Ialomiteanu A; Boak A; Rehm J
    Can J Psychiatry; 2010 Sep; 55(9):606-9. PubMed ID: 20840808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harms of prescription opioid use in the United States.
    Imtiaz S; Shield KD; Fischer B; Rehm J
    Subst Abuse Treat Prev Policy; 2014 Oct; 9():43. PubMed ID: 25352167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000.
    Fischer B; Murphy Y; Rudzinski K; MacPherson D
    Int J Drug Policy; 2016 Jan; 27():23-35. PubMed ID: 26359046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How many people in Canada use prescription opioids non-medically in general and street drug using populations?
    Popova S; Patra J; Mohapatra S; Fischer B; Rehm J
    Can J Public Health; 2009; 100(2):104-8. PubMed ID: 19839284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Interventions and Programs Targeting Appropriate Prescribing of Opioids.
    Moride Y; Lemieux-Uresandi D; Castillon G; de Moura CS; Pilote L; Faure M; Bernartsky S
    Pain Physician; 2019 May; 22(3):229-240. PubMed ID: 31151331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions.
    Fischer B; Jones W; Rehm J
    BMC Health Serv Res; 2014 Feb; 14():90. PubMed ID: 24572005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009.
    Fischer B; Nakamura N; Rush B; Rehm J; Urbanoski K
    Drug Alcohol Depend; 2010 Jun; 109(1-3):257-60. PubMed ID: 20197216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010.
    Fischer B; Jones W; Krahn M; Rehm J
    Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1269-77. PubMed ID: 21755568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns, trends and determinants of medical opioid utilization in Canada 2005-2020: characterizing an era of intensive rise and fall.
    Jones W; Kaoser R; Fischer B
    Subst Abuse Treat Prev Policy; 2021 Sep; 16(1):65. PubMed ID: 34521418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada.
    Fischer B; Varatharajan T; Shield K; Rehm J; Jones W
    Drug Alcohol Depend; 2018 Aug; 189():76-79. PubMed ID: 29886367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.